A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs

Author gokhancelik

Published on: 8 Ekim 2026

Published in: Explore

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.